Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Rehmannia glutinosa (Catalpol).
Rehmannia glutinosa, primarily through its iridoid glycoside catalpol, exerts potent neuroprotective and hypoglycemic effects by modulating the PI3K/Akt signaling pathway and suppressing pro-inflammatory cytokines.
91552
135.19 g/mol
-3.4
(2S)-2-amino-4-sulfanylbutanoic acid
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Rehmannia glutinosa (Catalpol) across standard consumer modalities.
The hygroscopic nature of concentrated Rehmannia extracts necessitates the use of moisture-barrier HPMC capsules and specialized desiccants to prevent powder caking.
High concentrations of native sugars and polysaccharides in the extract can disrupt the pectin cross-linking matrix, leading to structural instability and syneresis.
The high therapeutic dose required for catalpol-rich extracts exceeds the typical 50mg payload capacity of thin-film polymers, complicating the formulation of effective oral strips.
Ready to launch a product featuring Rehmannia glutinosa (Catalpol)? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Rehmannia glutinosa (Catalpol) extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Rehmannia glutinosa (Catalpol) payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation